Edwards Lifesciences Corp. shared positive fourth quarter 2017 earnings with adjusted sales of $909 million, marking 16 percent underlying growth for the full year and total year sales of more than $3.4 billion, and beating earlier estimates by analysts. Each geographic area the company operates in experienced growth in organic revenue based on increased uptake of its products, reported the company. First quarter of 2018 sales are expected to amount to $900 to $950 million.